Logo Organon & Co.

Organon & Co. (OGN) stock: analyst price target and their real reliability

Live quote · data updated Oct 14, 2026
Organon & Co. · Health Care · ref. ETF XLV · 40 calls · price $13.77
💬JPI AI AssistantTry it →
What the company does: Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.

📈 Organon & Co. (OGN) stock price

$13.77+44.0% over range
Oct 14, 25low $5.7 · high $13.81Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
0% recommend buying · 2 analysts
📊 JPI status : Organon & Co. is no longer in our current JPI rankings, but appeared in the past (2024) — its upside may be behind it. See the stocks picked in 2024 →

🎯 OGN price target & analyst consensus — price $13.77

The price target · all analysts combined (2 targets)
Highest target · 2 firms of 2$14+1.7%
Median target · of 2 targets$14+1.7%
Lowest target · 2 firms of 2$14+1.7%
Current price$13.77
⭐ What the most reliable analysts say

No reliable analyst is bullish on this stock right now. A “reliable” analyst is a firm that, on this sector, hits more than 55% of its targets and beats its sector. None of them sees upside here — which is exactly why this stock is in no JPI selection.

The consensus · 2 ratings (last 6 months)
Strong Buy00%
Buy00%
Hold2100%
Sell00%
Strong Sell00%
Go deeper on the analysts
All analysts (the consensus)  ·  vs  ·  the best (those who've been right)
💬 A question about Organon & Co.? The JPI assistant answers using our backtest data.

🏛️ Organon & Co. insider buying: who's buying and how much › open the full page

1 insider bought1 buys / 6 mo $353k

🔎 Detailed analyses

✅ Historical analyst reliability on OGN

Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.

Firm ↕ % right i ↕ Gain vs sector i ↕ Calls i ↕
Citigroup ↗ 100% +6.7% 2
Piper Sandler ↗ 60% +6.8% 5
B of A Securities ↗ 50% +5.5% 2
Barclays ↗ 50% -24.0% 2

📊 What $1,000 invested in Organon & Co. would be worth › open the full page

In short — $1,000 invested in Organon & Co. 10 years ago would be worth $406 today, i.e. -16%/yr on average. Best year: 2024 (+7%), worst: 2025 (-53%). Price performance, excluding dividends.

If I'd invested $1,000 in Organon & Co.

InvestmentWorth todayGain
1 years ago$874-13%
3 years ago$483-52%
5 years ago$406-59%
→ See Organon & Co.'s full return history + gain calculator

Return by year (Organon & Co.)

YearReturn$1,000 invested at year start
2026 (YTD)+86%$1,865 (+86%)
2025-53%$874 (-13%)
2024+7%$936 (-6%)
→ See Organon & Co.'s full return history + gain calculator
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.

📰 Recent news on Organon & Co.

Loading news…

📋 All analyst calls on OGN

BNP Paribas
Apr 29, 26
■ Neutral neutral · not a buy · 🎯$14
Price at call : $13.25 — gap to target +6%
Today : $13.77 — gap to target +2%
🎯 on OGN : no call matured yet · 📊 unranked overall
in progress (365j)
matures : Apr 29, 27
Piper Sandler ↗
Apr 28, 26
■ Neutral neutral · not a buy · 🎯$14
Price at call : $13.32 — gap to target +5%
Today : $13.77 — gap to target +2%
🎯 on OGN : 60% (5 calls matureds) · 📊 on Health : 45.4% · +6.7% (251 calls)
in progress (365j)
matures : Apr 28, 27
Barclays ↗
Feb 24, 26
▼ Underweight · 🎯$8
Price at call : $7.51 — upside +7%
Today : $13.77 — upside -42%
🎯 on OGN : 50% (2 calls matureds) · 📊 on Health : 37% · -8.6% (154 calls)
in progress (365j)
matures : Feb 24, 27
Barclays ↗
Dec 9, 25
▼ Underweight · 🎯$7.5
Price at call : $7.18 — upside +4%
Today : $13.77 — upside -46%
🎯 on OGN : 50% (2 calls matureds) · 📊 on Health : 37% · -8.6% (154 calls)
in progress (365j)
matures : Dec 9, 26
JP Morgan ↗
Nov 11, 25
▼ Underweight · 🎯$12
Price at call : $7.71 — upside +56%
Today : $13.77 — upside -13%
🎯 on OGN : 100% (1 call matured) · 📊 on Health : 49% · +6.7% (149 calls)
in progress (365j)
matures : Nov 11, 26
Morgan Stanley ↗
Nov 11, 25
■ Equal-Weight neutral · not a buy · 🎯$9
Price at call : $7.52 — gap to target +20%
Today : $13.77 — gap to target -35%
🎯 on OGN : no call matured yet · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : Nov 11, 26
Piper Sandler ↗
May 15, 25
▲ Overweight · 🎯$18
Price at call : $9.04 — upside +99%
Today : $13.77 — upside +31%
Expected +99% · Actual +48% · Reason (≥ +15%) : ✓ Yes
🎯 on OGN : 60% (5 calls matureds) · 📊 on Health : 45.4% · +6.7% (251 calls)
+48.4%
stock +48% · XLV +9%
matured May 15, 26
■ Equal-Weight neutral · not a buy · 🎯$10
Price at call : $9.13 — gap to target +10%
Today : $13.77 — gap to target -27%
🎯 on OGN : no call matured yet · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : May 5, 26
See the other 32 calls, newest to oldest
■ Equal-Weight neutral · not a buy · 🎯$15
Price at call : $11.43 — gap to target +31%
Today : $13.77 — gap to target +9%
🎯 on OGN : no call matured yet · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : Apr 9, 26
Barclays ↗
Feb 14, 25
▲ Overweight · 🎯$24
Price at call : $15.48 — upside +55%
Today : $13.77 — upside +74%
Expected +55% · Actual -53% · Reason (≥ +15%) : ✗ No
🎯 on OGN : 50% (2 calls matureds) · 📊 on Health : 37% · -8.6% (154 calls)
-53.0%
stock -53% · XLV +9%
matured Feb 14, 26
Morgan Stanley ↗
Feb 14, 25
■ Equal-Weight neutral · not a buy · 🎯$16
Price at call : $15.48 — gap to target +3%
Today : $13.77 — gap to target +16%
🎯 on OGN : no call matured yet · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : Feb 14, 26
JP Morgan ↗
Sep 6, 24
▼ Underweight · 🎯$20
Price at call : $20.49 — upside -2%
Today : $13.77 — upside +45%
Expected -2% · Actual -49% · Reason (≤ −15%) : ✓ Yes
🎯 on OGN : 100% (1 call matured) · 📊 on Health : 49% · +6.7% (149 calls)
+48.9%
stock -49% · XLV -10%
matured Sep 6, 25
Goldman Sachs ↗
May 6, 24
■ Neutral neutral · not a buy · 🎯$20
Price at call : $20.4 — gap to target -2%
Today : $13.77 — gap to target +45%
🎯 on OGN : 0% (1 call matured) · 📊 on Health : 51.9% · +5.8% (104 calls)
in progress (365j)
matures : May 6, 25
Goldman Sachs ↗
May 3, 24
■ Neutral neutral · not a buy · 🎯$20
Price at call : $20.68 — gap to target -3%
Today : $13.77 — gap to target +45%
🎯 on OGN : 0% (1 call matured) · 📊 on Health : 51.9% · +5.8% (104 calls)
in progress (365j)
matures : May 3, 25
Piper Sandler ↗
Apr 29, 24
▲ Overweight · 🎯$24
Price at call : $18.9 — upside +27%
Today : $13.77 — upside +74%
Expected +27% · Actual -30% · Reason (≥ +15%) : ✗ No
🎯 on OGN : 60% (5 calls matureds) · 📊 on Health : 45.4% · +6.7% (251 calls)
-30.4%
stock -30% · XLV -1%
matured Apr 29, 25
Goldman Sachs ↗
Feb 20, 24
■ Neutral neutral · not a buy · 🎯$18
Price at call : $18.53 — gap to target -3%
Today : $13.77 — gap to target +31%
🎯 on OGN : 0% (1 call matured) · 📊 on Health : 51.9% · +5.8% (104 calls)
in progress (365j)
matures : Feb 19, 25
Piper Sandler ↗
Nov 22, 23
▲ Overweight · 🎯$22
Price at call : $11.36 — upside +94%
Today : $13.77 — upside +60%
Expected +94% · Actual +35% · Reason (≥ +15%) : ✓ Yes
🎯 on OGN : 60% (5 calls matureds) · 📊 on Health : 45.4% · +6.7% (251 calls)
+34.5%
stock +35% · XLV +10%
matured Nov 21, 24
Goldman Sachs ↗
Nov 3, 23
■ Neutral neutral · not a buy · 🎯$16
Price at call : $13.3 — gap to target +20%
Today : $13.77 — gap to target +16%
🎯 on OGN : 0% (1 call matured) · 📊 on Health : 51.9% · +5.8% (104 calls)
in progress (365j)
matures : Nov 2, 24
Piper Sandler ↗
Oct 25, 23
▲ Overweight · 🎯$32
Price at call : $15.31 — upside +109%
Today : $13.77 — upside +132%
Expected +109% · Actual +12% · Reason (≥ +15%) : ✗ No
🎯 on OGN : 60% (5 calls matureds) · 📊 on Health : 45.4% · +6.7% (251 calls)
+12.1%
stock +12% · XLV +19%
matured Oct 24, 24
Morgan Stanley ↗
Oct 11, 23
■ Equal-Weight neutral · not a buy · 🎯$22
Price at call : $16.64 — gap to target +32%
Today : $13.77 — gap to target +60%
🎯 on OGN : no call matured yet · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : Oct 10, 24
Barclays ↗
Sep 21, 23
▲ Overweight · 🎯$28
Price at call : $18.58 — upside +51%
Today : $13.77 — upside +103%
Expected +51% · Actual +5% · Reason (≥ +15%) : ✗ No
🎯 on OGN : 50% (2 calls matureds) · 📊 on Health : 37% · -8.6% (154 calls)
+4.9%
stock +5% · XLV +19%
matured Sep 20, 24
■ Equal-Weight neutral · not a buy · 🎯$27
Price at call : $23.61 — gap to target +14%
Today : $13.77 — gap to target +96%
🎯 on OGN : no call matured yet · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : Aug 8, 24
■ Equal-Weight neutral · not a buy · 🎯$25
Price at call : $21.82 — gap to target +15%
Today : $13.77 — gap to target +82%
🎯 on OGN : no call matured yet · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : May 7, 24
Raymond James ↗
Mar 16, 23
▲ Outperform · 🎯$33
Price at call : $21.72 — upside +52%
Today : $13.77 — upside +140%
Expected +52% · Actual -16% · Reason (≥ +15%) : ✗ No
🎯 on OGN : 0% (1 call matured) · 📊 on Health : 39.7% · -2.1% (219 calls)
-15.8%
stock -16% · XLV +14%
matured Mar 15, 24
■ Equal-Weight neutral · not a buy · 🎯$24
Price at call : $24.35 — gap to target -1%
Today : $13.77 — gap to target +74%
🎯 on OGN : no call matured yet · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : Nov 4, 23
▼ Underperform · 🎯$25
Price at call : $23.31 — upside +7%
Today : $13.77 — upside +82%
Expected +7% · Actual -28% · Reason (≤ −15%) : ✓ Yes
🎯 on OGN : 50% (2 calls matureds) · 📊 on Health : 51.9% · +3.9% (156 calls)
+27.7%
stock -28% · XLV +6%
matured Oct 14, 23
Morgan Stanley ↗
Oct 12, 22
■ Equal-Weight neutral · not a buy · 🎯$27
Price at call : $24.03 — gap to target +12%
Today : $13.77 — gap to target +96%
🎯 on OGN : no call matured yet · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : Oct 12, 23
Piper Sandler ↗
Sep 6, 22
▲ Overweight · 🎯$34
Price at call : $28.71 — upside +18%
Today : $13.77 — upside +147%
Expected +18% · Actual -31% · Reason (≥ +15%) : ✗ No
🎯 on OGN : 60% (5 calls matureds) · 📊 on Health : 45.4% · +6.7% (251 calls)
-30.9%
stock -31% · XLV +5%
matured Sep 6, 23
■ Neutral neutral · not a buy · 🎯$37
Price at call : $31.5 — gap to target +17%
Today : $13.77 — gap to target +169%
🎯 on OGN : 50% (2 calls matureds) · 📊 on Health : 51.9% · +3.9% (156 calls)
in progress (365j)
matures : Aug 5, 23
■ Equal-Weight neutral · not a buy · 🎯$34
Price at call : $32.75 — gap to target +4%
Today : $13.77 — gap to target +147%
🎯 on OGN : no call matured yet · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : Jul 8, 23
Goldman Sachs ↗
Apr 27, 22
▲ Buy · 🎯$40
Price at call : $32.42 — upside +23%
Today : $13.77 — upside +190%
Expected +23% · Actual -25% · Reason (≥ +15%) : ✗ No
🎯 on OGN : 0% (1 call matured) · 📊 on Health : 51.9% · +5.8% (104 calls)
-24.9%
stock -25% · XLV +0%
matured Apr 27, 23
■ Equal-Weight neutral · not a buy · 🎯$35
Price at call : $36.2 — gap to target -3%
Today : $13.77 — gap to target +154%
🎯 on OGN : no call matured yet · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : Apr 6, 23
Morgan Stanley ↗
Feb 22, 22
■ Equal-Weight neutral · not a buy · 🎯$37
Price at call : $35.98 — gap to target +3%
Today : $13.77 — gap to target +169%
🎯 on OGN : no call matured yet · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : Feb 22, 23
Piper Sandler ↗
Oct 7, 21
■ Neutral neutral · not a buy · 🎯$35
Price at call : $32.84 — gap to target +7%
Today : $13.77 — gap to target +154%
🎯 on OGN : 60% (5 calls matureds) · 📊 on Health : 45.4% · +6.7% (251 calls)
in progress (365j)
matures : Oct 7, 22
▲ Buy · 🎯$43
Price at call : $34.56 — upside +24%
Today : $13.77 — upside +212%
Expected +24% · Actual -17% · Reason (≥ +15%) : ✗ No
🎯 on OGN : 50% (2 calls matureds) · 📊 on Health : 51.9% · +3.9% (156 calls)
-16.6%
stock -17% · XLV -6%
matured Sep 1, 22
Morgan Stanley ↗
Aug 16, 21
■ Equal-Weight neutral · not a buy · 🎯$35
Price at call : $34.33 — gap to target +2%
Today : $13.77 — gap to target +154%
🎯 on OGN : no call matured yet · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : Aug 16, 22
Citigroup ↗
Jul 23, 21
▲ Buy · 🎯$35
Price at call : $29.8 — upside +17%
Today : $13.77 — upside +154%
Expected +17% · Actual +10% · Reason (≥ +15%) : ✗ No
🎯 on OGN : 100% (2 calls matureds) · 📊 on Health : 44.9% · -4.4% (107 calls)
+10.1%
stock +10% · XLV -1%
matured Jul 23, 22
Citigroup ↗
Jul 22, 21
▲ Buy · 🎯$35
Price at call : $30.92 — upside +13%
Today : $13.77 — upside +154%
Expected +13% · Actual +3% · Reason (≥ +15%) : ✗ No
🎯 on OGN : 100% (2 calls matureds) · 📊 on Health : 44.9% · -4.4% (107 calls)
+3.4%
stock +3% · XLV -0%
matured Jul 22, 22
JP Morgan ↗
Jun 15, 21
■ Neutral neutral · not a buy · 🎯$38
Price at call : $31.81 — gap to target +19%
Today : $13.77 — gap to target +176%
🎯 on OGN : 100% (1 call matured) · 📊 on Health : 49% · +6.7% (149 calls)
in progress (365j)
matures : Jun 15, 22
Morgan Stanley ↗
Jun 11, 21
■ Equal-Weight neutral · not a buy · 🎯$33
Price at call : $29.65 — gap to target +11%
Today : $13.77 — gap to target +140%
🎯 on OGN : no call matured yet · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : Jun 11, 22

Frequently asked questions

Should I buy Organon & Co. stock?

This isn't buy advice. For Organon & Co., the analyst consensus is "Hold", with an average price target of $14.00 (+2% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 100% of the time (2 calls tracked on Organon & Co.). We show the numbers — you decide.

Is it too late to buy Organon & Co.? How high can it go?

The most bullish analyst target on Organon & Co. is $14.00 (+2% above today's price); the average is $14.00. That's the upside they see. Check how reliable those analysts have actually been on Organon & Co. on our site before trusting it.

Is Organon & Co. still a good buy?

The most useful "opinion" isn't an opinion — it's a track record: 4 analysts have a real record on Organon & Co., the best hitting 100% over 2 calls. Current consensus: "Hold". Make your call on data, not noise.

What has Organon & Co.'s past performance been?

Historical returns and a "how much if I had invested" calculator: OGN performance & returns.

Are insiders buying OGN stock?

Executives' and large holders' buys and sells, decoded: insider buying on OGN.

Other Health stocks

Go further

JPI AI Analyst AI assistant · JPI Invest
Answers based on the tool’s data · not financial advice · full version (free)